A new review published in The BMJ indicates that individuals discontinuing GLP-1 weight-loss drugs often regain their lost weight within two years, emphasizing the chronic nature of obesity. The study, led by University of Oxford researchers, found that weight rebound occurs faster than after behavioral interventions, prompting calls for integrated long-term management strategies.
The review analyzed 37 clinical trials involving more than 9,300 adults and was published on January 8, 2026. It has been widely reported by reliable news outlets such as CNN and Reuters, highlighting its timely relevance in the context of rising GLP-1 drug usage. The findings reveal that after stopping GLP-1 medications, weight regain proceeds at approximately 0.3 kilograms per month, which is about 0.7 pounds. This rate is significantly quicker than the regain observed in individuals who end diet and exercise programs, suggesting that the pharmacological effects are not sustained without continued treatment.
GLP-1 drugs, including Ozempic, Wegovy, Mounjaro, and Zepbound, mimic a natural hormone that regulates appetite and insulin secretion. Experts like Adam Collins from the University of Surrey explain that prolonged use may reduce the body’s sensitivity to GLP-1, increasing the likelihood of overeating upon discontinuation. Sam West, the study’s lead author, stated that this pattern reflects obesity as a chronic, relapsing condition rather than a failure of the medications. He advised against short-term drug use without comprehensive weight management plans that include lifestyle modifications.
Reuters corroborated these findings, reporting that health issues linked to obesity, such as cardiovascular risks, tend to return within two years after stopping the drugs. This underscores the importance of maintaining weight loss for long-term health benefits. With over 15 million Americans using GLP-1 drugs for weight loss, the study has profound implications for healthcare systems. It calls for anticipatory support, including nutritional guidance and behavioral therapy, to help patients sustain weight loss and prevent relapse.
Researchers note that some conclusions are based on modeled projections due to limited long-term data on drug discontinuation. Marie Spreckley from the University of Cambridge emphasized the need for further research to develop effective maintenance strategies alongside pharmacotherapy. In summary, this review reinforces that effective obesity management requires a holistic approach. GLP-1 drugs should be viewed as part of a sustained effort, integrating medication with healthy habits to mitigate weight regain and promote enduring health improvements.
